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Abstract Antibodies to purified recombinant PDHKII were 
used for ELISAs of PDHKII in mitochondrial extracts. In liver, 
hyperthyroidism elicited a 2.3-fold increase in PDHK activity 
(7'<0.01) which was accompanied by a significant 1.5-fold 
(P < 0.001) increase in the amount of mitochondrial immuno-
reactive PDHKII. In contrast, despite a stable 2.0-fold increase 
in cardiac PDHK activity (P < 0.001), the amount of mitochon-
drial immunoreactive PDHKII in heart was unaffected by 
hyperthyroidism. The mechanisms for long-term regulation of 
PDHK activity by thyroid hormones therefore differ fundamen-
tally between heart and liver. 
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1. Introduction 
The present study examines the molecular basis for the in-
creases in cardiac and hepatic pyruvate dehydrogenase kinase 
(PDHK) activities observed in response to hyperthyroidism in 
vivo using ELISAs for recombinant PDHKII, the major 
PDHK isoform in rat heart and essentially the sole PDHKII 
isoform in rat liver [1]. The aim was to determine whether the 
increased PDHK activities elicited by hyperthyroidism in vivo 
are due to changes in enzyme concentration and/or specific 
activity. 
PDHK catalyses the phosphorylation of the oc-subunit of 
the pyruvate dehydrogenase (PDH) component of the pyru-
vate dehydrogenase complex (PDHC), leading to its inactiva-
tion (reviewed in [2]). Increasing mitochondrial [acetyl-CoA]/ 
[CoA] and [NADH]/[NAD+] ratios activate PDHK, whereas 
increasing pyruvate concentrations suppress its activity [3]. It 
has been proposed previously that the long-term increase in 
PDHK activity in liver observed in response to prolonged 
starvation is a consequence of an increase in PDHK specific 
activity rather than increased PDHK protein (reviewed in [4] ; 
see also [5]). In experiments in tissue culture with hepatocytes 
and cardiac myocytes, fatty acids and cAMP have been shown 
to be possible mediators of the effects of starvation to increase 
PDH kinase activity [6-9]. 
Hyperthyroidism is associated with increased rates of fatty 
acid oxidation in these tissues [10,11]. The responses of car-
diac and hepatic PDHK to hyperthyroidism occur over a 
timescale comparable with those evoked by starvation (2-3 
days) [12,13], and may be important in facilitating the in-
creased Cori recycling characteristic of hyperthyroid state 
[10,14,15]. Studies with cultured cardiac myocytes [8] and hep-
atocytes [12] have demonstrated direct tissue effects of tri-
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iodothyronine (T3) to enhance PDHK activity. These effects 
are opposed by the further addition of insulin to the culture 
medium [8] and, in hepatocytes, by inhibition of mitochon-
drial fatty acid oxidation [12]. The similar characteristics of 
the long-term effects of starvation and hyperthyroidism to 
evoke stable increases in heart and liver PDHK activities ini-
tially suggested that they might share a common underlying 
mechanism, but subsequent evidence indicates that the effects 
of T3 is different to that of starvation. For example, additivity 
between the effects of starvation and hyperthyroidism to in-
crease cardiac PDHK activity would imply that separate 
mechanisms may be involved [8]. Also, in liver, although in-
creases in PDHK in response to hyperthyroidism are observed 
in the presence of a modest increase in hepatic cAMP concen-
trations, dose response studies demonstrated a dissociation 
between changes in PDHK activities and cAMP concentra-
tions [12]. It was nevertheless possible to detect a positive 
correlation between effects of T3 administration to elevate 
fatty acid supply and hepatic PDHK activity [12]. 
2. Materials and methods 
Biochemicals and chemicals were from Boehringer Corp. or from 
Sigma Chemical Corp., Poole, Dorset, UK. Recombinant PDHKII 
was kindly provided by Zeneca Pharmaceuticals, UK. Female Wistar 
rats were purchased from Charles River Ltd., Margate, Kent, UK. 
Female Albino Wistar rats were maintained on a 12 h light/12 h 
dark cycle (light from 10.00 h) and sampled in the absorptive state at 
the end of the dark phase. Rats were permitted free access to standard 
rodent diet (8% fat, 72% carbohydrate and 20% protein, by calories) 
and to water. 
Active PDHC (PDHa) activities were assayed spectrophotometri-
cally by coupling to arylamine acetyltransferase. Total PDHC was 
assayed as active complex after incubation of mitochondria for 
10 min in the absence of respiratory substrate. PDHK activities 
were assayed at pH 7.0 in extracts of heart mitochondria by the 
rate of ATP-dependent inactivation of fully activated PDHC and 
computed as apparent pseudo first order rate constants for ATP-
dependent PDHa inactivation [16]. Details of these methods are pro-
vided in [5,9,16]. 
Antibodies were raised in New Zealand White rabbits to purified 
recombinant PDHKII (provided by Zeneca Pharmaceuticals) ad-
judged to be 49% pure on densitometric scanning of an SDS-PAGE 
gel stained with coomassie blue. The priming dose was 10 μg of 
protein in Freund's complete adjuvant given subcutaneously at four 
dorsal sites. After 6 weeks, boosting injections (10 μg) in Freund's 
incomplete adjuvant were given at 4-weekly intervals. Blood was 
removed from an ear vein at 10 days after boosts. The serum obtained 
was screened for antibodies by Western blotting from SDS/PAGE 
using preimmune serum as control. The antiserum was specific 
to PDHKII with negligible cross-reaction to PDKI as assessed by 
Western blots (results not shown). ELISA assays were performed us-
ing clarified extracts of liver or heart mitochondria as described in 
[17]. 
Results are means ± standard error (S.E.M.) for the numbers of 
observations indicated. Statistical analyses were made with StatView 
(Abacus Concepts, Inc., Berkeley, CA). Statistical significance of dif-
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ferences between groups was assessed by Student's unpaired г-test. 
Curve-fitting was carried out using Fig P software. 
3. Results 
3.1. PDHK activities in heart and liver mitochondria after T3 
treatment in vivo 
PDHK activity measured in extracts of liver mitochondria 
was increased from by 2.3-fold, from 1.83 ±0.28 min - 1 
(и = 10) to 3.82 ± 0.45 min"1 (и = 10) (P < 0.01) after treatment 
with T3 for 3 days. PDHK activity measured in extracts of 
cardiac mitochondria was increased from 1.01 ±0.13 min - 1 
(n = 7) to 2.05 ± 0.22 min"1 (n = 7) (P < 0.001) after treatment 
with T3 for 3 days. As reported previously [8,12,18], total 
PDHC activities in heart and liver mitochondria were unaf-
fected by hyperthyroidism (results not shown). 
3.2. ELISAs of PDHKII in mitochondrial extracts 
We examined whether the PDHK activity increases in liver 
and heart were accompanied by increases in PDHKII enzyme 
concentrations. The results for ELISAs of PDHKII in clari-
fied extracts of liver mitochondria from euthyroid and hyper-
thyroid rats are shown in Fig. la. In these experiments, we 
compared the two groups (hyperthyroid versus euthyroid) di-
rectly through side-by-side comparison, in the same well block 
and over the same range of PDHC activities (from 0.03 to 
5 m-units/well). The amount of immunoreactive PDHKII in 
mitochondrial extracts from livers of fed hyperthyroid rats 
was reproducibly and consistently increased over the entire 
range of PDHC activities. Individual points for the ELISA 
are shown in the inset to Fig. lb. Immunoreactive PDHKII 
(a) 
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Fig. 1. ELISA of PDHKII in extracts of mitochondria from livers 
of euthyroid (E) and hyperthyroid (H) rats. Mitochondria from eu-
thyroid rats (open symbols) and hyperthyroid rats (closed symbols) 
were extracted by freezing and thawing (three times) in mitochon-
drial extraction buffer. The extracts were clarified by centrifugation 
and ELISAs performed with pairs of extracts as described in [15]. 
Data are shown in (a) and ratios of hyperthyroid/euthyroid (H/E; 
means ± S.E.M.) for individual points in the ELISA in (b). Results 
are means ± S.E.M. for ELISAs of four separate mitochondrial 
preparations (each with four wells for each PDH complex activity). 
Statistically significant differences between euthyroid and hyperthy-
roid rats are indicated by: *P<0.05. 
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Fig. 2. ELISA of PDHKII in extracts of mitochondria prepared 
from hearts of euthyroid (E) and hyperthyroid (H) rats. Mitochon-
dria from euthyroid rats (open symbols) and hyperthyroid rats 
(closed symbols) were extracted by freezing and thawing (three 
times) in mitochondrial extraction buffer. The extracts were clarified 
by centrifugation and ELISAs performed with pairs of extracts as 
described in [15]. Data are shown in (a) and ratios of hyperthyroid/ 
euthyroid (H/E; means± S.E.M.) for individual points in the ELISA 
in (b). Results are means ± S.E.M. for ELISAs of four separate mi-
tochondrial preparations (each with four wells for each PDH com-
plex activity). 
protein was 1.3- to 1.8-fold greater in extracts from hyper-
thyroid (H) rats than that in extracts from euthyroid (E) rats 
with a mean ratio of activities at individual points in the 
ELISA of 1.503 ±0.018 (и = 40). 
Fig. 2a shows the results for ELISA assay of PDHKII in 
clarified extracts of heart mitochondria from euthyroid and 
hyperthyroid rats. As with the liver, the assay was again con-
ducted over a range of PDH activities (from 0.03 to 5 m-units/ 
well). The amount of immunoreactive PDHKII in mitochon-
drial extracts from hearts of hyperthyroid rats (H) was ~ 
similar to that in extracts from the euthyroid rats (E) with 
no significant difference between the individual values (see the 
inset to Fig. 2b). 
4. Discussion 
PDHK comprises one component of the regulatory phos-
phorylation cycle of mammalian PDHC. It comprises 2 dis-
similar a- and ß-subunits. The ce-subunit is the catalytic sub-
unit. PDHKa is partly tightly bound to PDHC, and is partly 
free in the mitochondrial matrix. The more loosely bound 
PDHK is identical with the so-called PDHK activator pro-
tein, КАР [19,20]. Prolonged starvation causes an increase in 
PDHK activity and it was concluded from studies employing 
polyclonal antibodies raised to PDHKa purified from livers of 
48 h starved rats that no significant differences in the concen-
tration of this protein existed between livers from fed and 
starved rats [17]. Culture of cardiac myocytes or hepatocytes 
prepared from fed rats with a fatty acid (и-octanoate or pal-
mitate) and dibutyryl cyclic AMP (Bt2cAMP) for 24 h mimics 
the long-term effect of starvation to increase PDHK activity 
[6,7]. Hyperthyroidism also leads to stable increases in PDHK 
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[8,12] and the responses of cardiac and hepatic PDHK to 
hyperthyroidism occur over a similar timescale [8,12]. Also, 
studies with cultured cardiac myocytes [8] and hepatocytes 
[12] have shown direct effects of tri-iodothyronine (T3) to 
enhance PDHK activity. 
Multiple isoenzymic forms of PDHK have been identified 
[1,21]. PDHKI and PDHKII have been detected in rat tissues. 
In tissues tested thus far, the expression of PDHKII mRNA is 
higher than that of either PDHKI (rat, human) or PDHKIII 
(human) [1,21]. PDHKI and PDHKII are both present in rat 
heart, but PDHKII is the only isoform of PDHK detected in 
significant quantity in rat liver to date [1]. The present study 
examined whether the concentration of a specific isoform of 
PDHK, PDHKII (MT = 45 kDa), was altered by hyperthyroid-
ism in the fed state, either in heart or in liver. 
Experiments in vivo have demonstrated that the long-term 
response of PDHK activity to starvation is blocked by cyclo-
heximide [16], suggestive of an effect at the level of transcrip-
tion and/or translation. In addition, cycloheximide almost to-
tally inhibits the 3-fold increase in PDHK activity induced by 
Bt2cAMP in cultured hepatocytes [17]. Here we demonstrate 
that the long-term action of hyperthyroidism in vivo to 
increase hepatic PDHK activity is associated with a stable 
increase in the concentration of hepatic PDHKII. Further 
studies will resolve whether the long-term effect of hyper-
thyroidism to increase hepatic PDHKII concentration is ex-
erted at the level of transcription; however, it is known that 
the T3 receptor is a member of the steroid/thyroid/retinoid 
superfamily of nuclear hormone receptors and T3 is capable 
of inducing gene expression via a T3 response element. 
It would be predicted that, in the absence of any change in 
the specific activity of hepatic PDHK in hyperthyroidism, the 
increase in PDHK activity would be paralleled by an increase 
in PDHKII concentration of similar magnitude. The mean 
fold increase in PDHKII activity elicited by hyperthyroidism 
(2.3 ±0.3) exceeds the mean fold increase in PDHKII protein 
(1.5 ±0.1). Effects of T3 to increase PDHK in cultured hep-
atocytes can be reversed by inhibition of mitochondrial fatty 
acid oxidation [12], but the effect of fatty acids to increase 
PDHK activity in cultured hepatocytes is not blocked signifi-
cantly by cycloheximide [17]. Taken together, the results sug-
gest that post-translational modification secondary to en-
hanced fatty acid oxidation may, in conjunction with 
increased PDHKII expression, participate in achieving the 
overall enhancement of hepatic PDHK activity elicited by 
hyperthyroidism. Thus, a dual mechanism of enhanced specif-
ic activity in association with increased PDHKII protein op-
erates in liver to increase PDHK activity in response to hyper-
thyroidism. 
The current study reveals that T3 administration increases 
cardiac PDHK activity, without any increase in the tissue 
concentration of PDHKII. The results of the ELISA for 
PDHII exclude a change in PDHKII concentration as the 
mechanism by which cardiac PDHK activity is stably en-
hanced in hyperthyroidism. However, in contrast with rat 
liver (which contains PDHKII), rat heart contains PDHKI 
(Μτ = 48 kDa), which exhibits approx. 70% sequence homol-
ogy with PDHKII, in significant amounts. Our data do not 
exclude the possibility of a change in the cardiac concentra-
tion of PDHKI or a further PDHK isoform. Alternatively, 
the effect of hyperthyroidism to increase cardiac PDHK ac-
tivity may be achieved through post-translational modifica-
tion of PDHKI/II, with a concomitant increase in PDHK 
specific activity. 
In summary, our data demonstrate that the effect of hyper-
thyroidism to increase hepatic PDHK activity is associated 
with a specific increase in PDHKII protein, although a paral-
lel increase in PDHK specific activity is not excluded. In ad-
dition, PDHK may be added to the cohort of many gene 
products whose expression in liver is regulated by changes 
in thyroid status. The study also clearly demonstrates that 
hyperthyroidism increases the activity of cardiac PDHK with-
out any change in the tissue concentration of PDHKII (one of 
the major isoforms of PDHK in rat heart), as assessed by 
ELISAs of PDHKII in mitochondrial extracts. It can there-
fore be concluded that the long-term regulation of PDHK 
differs between these important tissues, and that results and 
conclusions obtained with one tissue preparation cannot nec-
essarily be extrapolated to another. 
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